Study: NCT00442936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant potassium 150 mg
Description: Telcagepant 150 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant potassium 300 mg
Description: Telcagepant 300 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolmitriptan 5 mg
Description: Zolmitriptan 5 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to telcagepant 150 mg
Description: Placebo to match telcagepant 150 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to telcagepant 150 mg
Description: Placebo to match telcagepant 150 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to telcagepant 150 mg
Description: Placebo to match telcagepant 150 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tecagepant 300 mg
Description: Placebo to match tecagepant 300 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tecagepant 300 mg
Description: Placebo to match tecagepant 300 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to tecagepant 300 mg
Description: Placebo to match tecagepant 300 mg liquid-filled soft gel capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to zolmitriptan 5 mg
Description: Placebo to match zolmitriptan 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zolmitriptan 5 mg
Description: Placebo to match zolmitriptan 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zolmitriptan 5 mg
Description: Placebo to match zolmitriptan 5 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.